The Promise of Biomarkers in Diagnosing Major Depression in Primary Care: the Present and Future

Current Psychiatry Reports

Volumn 17, Issue 8, 2015, Pages

  Redei, Eva E ^a   Mehta, Neha S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomarkers; Major depression; Methylation; Primary care; Proteomics; Transcriptomics

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN E; BETA INTERFERON; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; CYSTATIN C; CYTOKINE; DNA; HEMOPEXIN; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; PROSTAGLANDIN D2; RNA; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TUMOR NECROSIS FACTOR; VITAMIN D BINDING PROTEIN; GENETIC MARKER;

5HTR2A GENE; 5HTT GENE; ADCY3 GENE; BDNF GENE; CADM1 GENE; CCL24 GENE; CCR6 GENE; DGKA GENE; DNA METHYLATION; DUSP1 GENE; EDG2 GENE; ERBB3 GENE; FAM46A GENE; FGFR1 GENE; FKB15 GENE; FZD3 GENE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; HUMAN; IGFBP4 GENE; IGFBP6 GENE; IGSF4A GENE; KIAA1539 GENE; MAG GENE; MAJOR DEPRESSION; MARCKS GENE; MBP GENE; NONHUMAN; PMP22 GENE; PRIMARY MEDICAL CARE; PROTEOMICS; PSME1 GENE; PTPRM GENE; RAPH1 GENE; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SLC6A4 GENE; STK32C GENE; TLR7 GENE; TRANSCRIPTOMICS; UGT8 GENE; ZBTB16 GENE; ZBTB20 GENE; BLOOD; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION PROFILING; PRIMARY HEALTH CARE; PROCEDURES; STANDARDS; TRENDS;

BIOMARKERS; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; PRIMARY HEALTH CARE; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 84935038543     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-015-0601-1     Document Type: Review

References (73)

1. Kupfer DJ, Frank E, Perel JM. The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry. 1989;46(9):771–5.
2. Halfin A. Depression: the benefits of early and appropriate treatment. Am J Manage Care. 2007;13(4):S92–7.
3. Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: a review of the evidence. Am J Psychiatry. 2002;159(6):909–16.
4. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry. 1993;150(5):734–41.
5. King M, Nazareth I, Levy G, Walker C, Morris R, Weich S, et al. Prevalence of common mental disorders in general practice attendees across Europe. Br J Psychiatry. 2008;192(5):362–7. doi:10.1192/bjp.bp.107.039966.
6. Mitchell AJ. Are one or two simple questions sufficient to detect depression in cancer and palliative care? a Bayesian meta-analysis. Br J Cancer. 2008;98(12):1934–43. doi:10.1038/sj.bjc.6604396.
7. Chan MK, Gottschalk MG, Haenisch F, Tomasik J, Ruland T, Rahmoune H, et al. Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog Neurobiol. 2014;122:45–72. doi:10.1016/j.pneurobio.2014.08.002.
8. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014;311(4):392–404. doi:10.1001/jama.2013.284664.
9. Ziegler A, Koch A, Krockenberger K, Grosshennig A. Personalized medicine using DNA biomarkers: a review. Hum Genet. 2012;131(10):1627–38. doi:10.1007/s00439-012-1188-9.
10. McCarthy MI, Hirschhorn JN. Genome-wide association studies: potential next steps on a genetic journey. Hum Mol Genet. 2008;17(2):R156–65. doi:10.1093/hmg/ddn289.
11. Major Depressive Disorder Working Group of the Psychiatric GC, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 2013;18(4):497–511. doi:10.1038/mp.2012.21.
12. Hek K, Demirkan A, Lahti J, Terracciano A, Teumer A, Cornelis MC, et al. A genome-wide association study of depressive symptoms. Biol Psychiatry. 2013;73(7):667–78. doi:10.1016/j.biopsych.2012.09.033.
13. Flint J, Kendler KS. The genetics of major depression. Neuron. 2014;81(3):484–503. doi:10.1016/j.neuron.2014.01.027. The most recent critical review on the state of research identifying genetic contribution to disease susceptibility. Specific emphasis on disease subtypes.
14. Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, et al. Evidence for a relationship between genetic variants at the brain-derived Neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry. 2005;58(4):307–14. doi:10.1016/j.biopsych.2005.04.006.
15. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry. 2009;66(5):488–97. doi:10.1001/archgenpsychiatry.2009.38.
16. Serretti A, Drago A, De Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem. 2007;14(19):2053–69.
17. Levinson DF. The genetics of depression: a review. Biol Psychiatry. 2006;60(2):84–92. doi:10.1016/j.biopsych.2005.08.024.
18. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry. 2009;14(12):1105–18. doi:10.1038/mp.2009.92.
19. Cervilla JA, Rivera M, Molina E, Torres-Gonzalez F, Bellon JA, Moreno B, et al. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(8):912–7. doi:10.1002/ajmg.b.30455.
20. Gyekis JP, Yu W, Dong S, Wang H, Qian J, Kota P, et al. No association of genetic variants in BDNF with major depression: a meta- and gene-based analysis. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(1):61–70. doi:10.1002/ajmg.b.32122.
21. Jin C, Xu W, Yuan J, Wang G, Cheng Z. Meta-analysis of association between the -1438A/G (rs6311) polymorphism of the serotonin 2A receptor gene and major depressive disorder. Neurol Res. 2013;35(1):7–14. doi:10.1179/1743132812Y.0000000111.
22. Byrne EM, Carrillo-Roa T, Henders AK, Bowdler L, McRae AF, Heath AC, et al. Monozygotic twins affected with major depressive disorder have greater variance in methylation than their unaffected co-twin. Transcult Psychiatry. 2013;3, e269. doi:10.1038/tp.2013.45.
23. Dempster EL, Wong CC, Lester KJ, Burrage J, Gregory AM, Mill J, et al. Genome-wide methylomic analysis of monozygotic twins discordant for adolescent depression. Biol Psychiatry. 2014;76(12):977–83. doi:10.1016/j.biopsych.2014.04.013.
24. Davies MN, Krause L, Bell JT, Gao F, Ward KJ, Wu H, et al. Hypermethylation in the ZBTB20 gene is associated with major depressive disorder. Genome Biol. 2014;15(4):R56. doi:10.1186/gb-2014-15-4-r56.
25. Numata S, Ishii K, Tajima A, Iga J, Kinoshita M, Watanabe S, et al. Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles: discovery and validation. Epigenetics. 2015;10(2):135–41. doi:10.1080/15592294.2014.1003743. Unbiased genome-wide DNA methylation profiling demonstrated that methylation markers could serve as blood-based biomarkers for MDD.
26. Kang HJ, Kim JM, Stewart R, Kim SY, Bae KY, Kim SW, et al. Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:23–8. doi:10.1016/j.pnpbp.2013.01.006.
27. Zhao J, Goldberg J, Bremner JD, Vaccarino V. Association between promoter methylation of serotonin transporter gene and depressive symptoms: a monozygotic twin study. Psychosom Med. 2013;75(6):523–9. doi:10.1097/PSY.0b013e3182924cf4.
28. Okada S, Morinobu S, Fuchikami M, Segawa M, Yokomaku K, Kataoka T, et al. The potential of SLC6A4 gene methylation analysis for the diagnosis and treatment of major depression. J Psychiatr Res. 2014;53:47–53. doi:10.1016/j.jpsychires.2014.02.002.
29. D’Addario C, Dell’Osso B, Galimberti D, Palazzo MC, Benatti B, Di Francesco A, et al. Epigenetic modulation of BDNF gene in patients with major depressive disorder. Biol Psychiatry. 2013;73(2):e6–7. doi:10.1016/j.biopsych.2012.07.009.
30. Dell’Osso B, D’Addario C, Carlotta Palazzo M, Benatti B, Camuri G, Galimberti D, et al. Epigenetic modulation of BDNF gene: differences in DNA methylation between unipolar and bipolar patients. J Affect Disord. 2014;166:330–3. doi:10.1016/j.jad.2014.05.020.
31. Song Y, Miyaki K, Suzuki T, Sasaki Y, Tsutsumi A, Kawakami N, et al. Altered DNA methylation status of human brain derived neurotrophis factor gene could be useful as biomarker of depression. Am J Med Genet B Neuropsychiatr Genet. 2014;165B(4):357–64. doi:10.1002/ajmg.b.32238.
32. Hepgul N, Cattaneo A, Zunszain PA, Pariante CM. Depression pathogenesis and treatment: what can we learn from blood mRNA expression? BMC medicine. 2013;11:28. doi:10.1186/1741-7015-11-28. Review of the candidate biological process approach in identifying biomarkers for MDD. Focusing on inflammation, gluccocorticoid function-related and neuropasticity domains.
33. Mostafavi S, Battle A, Zhu X, Potash JB, Weissman MM, Shi J, et al. Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. Mol Psychiatry. 2014;19(12):1267–74. doi:10.1038/mp.2013.161. A large transcriptomic study using RNA-Seq from whole blood. The findings confirmed the role of altered immune-signaling in the pathophysiological process to MDD.
34. Liu Z, Li X, Sun N, Xu Y, Meng Y, Yang C, et al. Microarray profiling and co-expression network analysis of circulating lncRNAs and mRNAs associated with major depressive disorder. PLoS One. 2014;9(3):e93388. doi:10.1371/journal.pone.0093388.
35. Garbett KA, Vereczkei A, Kalman S, Brown JA, Taylor WD, Faludi G, et al. Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression. Biol Psychiatry. 2015;77(3):256–65. doi:10.1016/j.biopsych.2014.05.015. From dermal fibroblast, using microarray analysis the authors identified mRNA and miRNA as candidate biomarkers. They also confirmed the differential expression by quantitative RT-PCR and identified targets for the miRNA candidate markers.
36. Spijker S, Van Zanten JS, De Jong S, Penninx BW, van Dyck R, Zitman FG, et al. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry. 2010;68(2):179–86. doi:10.1016/j.biopsych.2010.03.017.
37. Menke A, Arloth J, Putz B, Weber P, Klengel T, Mehta D, et al. Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology. 2012;37(6):1455–64. doi:10.1038/npp.2011.331.
38. Powell TR, McGuffin P, D’Souza UM, Cohen-Woods S, Hosang GM, Martin C, et al. Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients. PLoS One. 2014;9(3), e91076. doi:10.1371/journal.pone.0091076.
39. Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry. 2009;14(2):156–74. doi:10.1038/mp.2008.11.
40. Redei EE, Andrus BM, Kwasny MJ, Seok J, Cai X, Ho J, et al. Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy. Transl Psychiatry. 2014;4, e442. doi:10.1038/tp.2014.66.
41. Pajer K, Andrus BM, Gardner W, Lourie A, Strange B, Campo J, et al. Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression. Transl Psychiatry. 2012;2, e101. doi:10.1038/tp.2012.26.
42. Ditzen C, Tang N, Jastorff AM, Teplytska L, Yassouridis A, Maccarrone G, et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology. 2012;37(4):1013–25. doi:10.1038/npp.2011.285.
43. Alawam K, Dudley E, Donev R, Thome J. Protein and peptide profiling as a tool for biomarker discovery in depression. Electrophoresis. 2012;33(24):3830–4. doi:10.1002/elps.201200248. Proteomic approach identified three peptides as potential biomarker candidates, but the authors did not identify them!.
44. Lichtblau N, Schmidt FM, Schumann R, Kirkby KC, Himmerich H. Cytokines as biomarkers in depressive disorder: current standing and prospects. Int Rev Psychiatry. 2013;25(5):592–603. doi:10.3109/09540261.2013.813442.
45. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229. doi:10.1016/j.neuroscience.2013.04.060.
46. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012;139(3):230–9. doi:10.1016/j.jad.2011.08.003.
47. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry. 2013;18(3):332–9. doi:10.1038/mp.2011.166. Assessment of a commercially available serum-based biomarker test. The details of the test need more transparency.
48. Baune BT, Smith E, Reppermund S, Air T, Samaras K, Lux O, et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney memory and aging study. Psychoneuroendocrinology. 2012;37(9):1521–30. doi:10.1016/j.psyneuen.2012.02.006.
49. Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X, et al. Plasma biomarkers of depressive symptoms in older adults. Transcult Psychiatry. 2012;2, e65. doi:10.1038/tp.2011.63.
50. Mullins N, Hodgson K, Tansey KE, Perroud N, Maier W, Mors O, et al. Investigation of blood mRNA biomarkers for suicidality in an independent sample. Transcult Psychiatry. 2014;4, e474. doi:10.1038/tp.2014.112.
51. Niculescu AB, Levey D, Le-Niculescu H, Niculescu E, Kurian SM, Salomon D. Psychiatric blood biomarkers: avoiding jumping to premature negative or positive conclusions. Mol Psychiatry. 2015;20(3):286–8. doi:10.1038/mp.2014.180. A sobering warning call that can be interpreted as self-serving.
52. Keri S, Szabo C, Kelemen O. Blood biomarkers of depression track clinical changes during cognitive-behavioral therapy. J Affect Disord. 2014;164:118–22. doi:10.1016/j.jad.2014.04.030.
53. Booth B, Arnold ME, DeSilva B, Amaravadi L, Dudal S, Fluhler E, et al. Workshop report: crystal city v-quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance. AAPS J. 2015;17(2):277–88. doi:10.1208/s12248-014-9696-2.
54. Hunter DJ, Losina E, Guermazi A, Burstein D, Lassere MN, Kraus V. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr Drug Targets. 2010;11(5):536–45.
55. Lin E, Tsai SJ. Genome-wide microarray analysis of gene expression profiling in major depression and antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2015. doi:10.1016/j.pnpbp.2015.02.008.
56. Guintivano J, Arad M, Gould TD, Payne JL, Kaminsky ZA. Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. Mol Psychiatry. 2014;19(5):560–7. doi:10.1038/mp.2013.62.
57. Friess E, Schmid D, Modell S, Brunner H, Lauer CJ, Holsboer F, et al. Dex/CRH-test response and sleep in depressed patients and healthy controls with and without vulnerability for affective disorders. J Psychiatr Res. 2008;42(14):1154–62. doi:10.1016/j.jpsychires.2008.01.005.
58. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry. 2008;13(8):800–12. doi:10.1038/mp.2008.59.
59. Hashimoto K. Brain-derived Neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci. 2010;64(4):341–57. doi:10.1111/j.1440-1819.2010.02113.x.
60. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case–control collections. PLoS One. 2010;5(2), e9166. doi:10.1371/journal.pone.0009166.
61. U.S. Department of Health and Human Services FaDA. Guidance for Industry. Pharmacogenomic Data Submissions 2005.
62. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312–28. doi:10.1007/s11095-005-9045-3.
63. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605–13.
64. Malhi GS. ICD future. The Australian and New Zealand journal of psychiatry. 2014;48(2):107–9. doi:10.1177/0004867414521720.
65. Singh I, Rose N. Biomarkers in psychiatry. Nature. 2009;460(7252):202–7. doi:10.1038/460202a.
66. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157(10):1552–62.
67. Sullivan PF, Daly MJ, O’Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet. 2012;13(8):537–51. doi:10.1038/nrg3240.
68. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747–53. doi:10.1038/nature08494.
69. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–35. doi:10.1126/science.1132939.
70. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science translational medicine. 2011;3(96):96–77. doi:10.1126/scitranslmed.3001318.
71. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010;107(33):14621–6. doi:10.1073/pnas.1000138107.
72. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Science translational medicine. 2011;3(96):96–76. doi:10.1126/scitranslmed.3002648.
73. Andrus BM, Blizinsky K, Vedell PT, Dennis K, Shukla PK, Schaffer DJ, et al. Gene expression patterns in the hippocampus and amygdala of endogenous depression and chronic stress models. Mol Psychiatry. 2012;17(1):49–61. doi:10.1038/mp.2010.119.